Biblio
Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. Lancet Neurol. 2021;20(11):917-929.
Haploidentical hemopoietic cell transplantation for myelofibrosis, in ruxolitinib era. Transplant Cell Ther. 2022.
.